171 related articles for article (PubMed ID: 2200152)
1. [Sensitivity and specificity of CEA, Ca 15-3 and MCA levels in visceral breast carcinoma metastasis].
Delbrück H; Hagen-Aukamp C; Braun G
Strahlenther Onkol; 1990 Jul; 166(7):457-9. PubMed ID: 2200152
[TBL] [Abstract][Full Text] [Related]
2. Clinical evaluation of M43: a novel cancer-associated mucin epitope.
Goodgame R; Kiefe C; Rose E; Sutton F; Brown J; Alpert E
Cancer Res; 1993 Jun; 53(12):2803-9. PubMed ID: 7684947
[TBL] [Abstract][Full Text] [Related]
3. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
[TBL] [Abstract][Full Text] [Related]
4. Relative operating characteristic analysis and group modeling for tumor markers: comparison of CA 15.3, carcinoembryonic antigen, and mucin-like carcinoma-associated antigen in breast carcinoma.
Silver HK; Archibald BL; Ragaz J; Coldman AJ
Cancer Res; 1991 Apr; 51(7):1904-9. PubMed ID: 2004374
[TBL] [Abstract][Full Text] [Related]
5. Expression of monoclonal antibody-defined tumor markers in four carcinomas.
Wu JT
Ann Clin Lab Sci; 1989; 19(1):17-26. PubMed ID: 2916833
[TBL] [Abstract][Full Text] [Related]
6. Expression of mucin-like carcinoma-associated antigen in the cyst fluid differentiates mucinous from nonmucinous pancreatic cysts.
Sperti C; Pasquali C; Pedrazzoli S; Guolo P; Liessi G
Am J Gastroenterol; 1997 Apr; 92(4):672-5. PubMed ID: 9128321
[TBL] [Abstract][Full Text] [Related]
7. [Clinical evaluation of tumor markers in patients with colorectal cancer].
Naritaka Y; Ogawa K; Matsumoto N; Hosokawa T; Kikuchi T; Koyama N; Haga S; Kajiwara T; Sakakibara N
Gan No Rinsho; 1987 Aug; 33(10):1274-80. PubMed ID: 2444727
[TBL] [Abstract][Full Text] [Related]
8. [Comparison of the tumor markers CEA and CA 19-9 in colorectal diagnosis].
Heptner G; Domschke S; Krapf F; Schneider MU; Iro H; Domschke W
Dtsch Med Wochenschr; 1984 Aug; 109(35):1309-12. PubMed ID: 6590287
[TBL] [Abstract][Full Text] [Related]
9. [Clinical evaluation of the tumor marker CA 19-9 in comparison with carcinoembryonic antigen (CEA) in surgical pre- and postoperative diagnosis].
Lorenz M; Happ J; Hottenrott C; Maul FD; Baum RP; Hör G; Encke A
Nuklearmedizin; 1986 Feb; 25(1):9-14. PubMed ID: 3459133
[TBL] [Abstract][Full Text] [Related]
10. [Tumor markers in the upper intestinal tract--stomach and pancreas].
Pointner R; Conrad F; Schwab G
Wien Klin Wochenschr; 1989 Jul; 101(14):482-4. PubMed ID: 2773485
[TBL] [Abstract][Full Text] [Related]
11. Serum CEA, CA 15-3, and MCA in breast cancer patients: a clinical evaluation.
Repetto L; Onetto M; Gardin G; Costanzi B; Giudici S; Vitiello E; Merlini L; Naso C; Zannini C; Paganuzzi M
Cancer Detect Prev; 1993; 17(3):411-5. PubMed ID: 8402728
[TBL] [Abstract][Full Text] [Related]
12. [Neoplasm markers useful for diagnosis and monitoring of colonic neoplasms].
Ławicki S; Mroczko B; Szmitkowski M
Postepy Hig Med Dosw; 2002; 56(5):617-34. PubMed ID: 12596691
[TBL] [Abstract][Full Text] [Related]
13. Mammary serum antigen (MSA), Ca 549, CA 15-3 and CEA in breast cancer preoperative sensitivity and correlation to prognostic factors.
Heinze T; Schürenkämper P; Minguillon C; Lichtenegger W
Anticancer Res; 1997; 17(4B):2953-4. PubMed ID: 9329573
[TBL] [Abstract][Full Text] [Related]
14. Early diagnosis of breast cancer dissemination by tumor markers follow-up and method of prediction.
Nekulová M; Simícková M; Pecen L; Eben K; Vermousek I; Stratil P; Cernoch M; Lang B
Neoplasma; 1994; 41(2):113-8. PubMed ID: 8208314
[TBL] [Abstract][Full Text] [Related]
15. Comparison of tumour markers TAG 12 with CA 15-3 and MCA in breast cancer diagnosis.
Eskelinen M; Hippelainen M; Salmela E; Paajanen H; Carlsson L; Jonsson P; Alhava E
Anticancer Res; 1992; 12(1):39-42. PubMed ID: 1567179
[TBL] [Abstract][Full Text] [Related]
16. A new tumor marker MCA in breast cancer diagnosis.
Eskelinen M; Tikanoja S; Collan Y
Anticancer Res; 1988; 8(4):665-8. PubMed ID: 3178156
[TBL] [Abstract][Full Text] [Related]
17. Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow-up and monitoring therapeutic response in breast cancer patients.
Lauro S; Trasatti L; Bordin F; Lanzetta G; Bria E; Gelibter A; Reale MG; Vecchione A
Anticancer Res; 1999; 19(4C):3511-5. PubMed ID: 10629644
[TBL] [Abstract][Full Text] [Related]
18. [Immunohistochemical study of the localization and distributional patterns of CA 19-9 and CEA in primary and metastatic nodal lesions of gastrointestinal cancer].
Deguchi H; Tabuchi Y; Saitoh Y
Gan No Rinsho; 1990 Jul; 36(8):890-4. PubMed ID: 1694901
[TBL] [Abstract][Full Text] [Related]
19. MCA performance in preoperative breast cancer patients.
Donadeo A; Micelli G; Quaranta M; Atlante A; Schittulli F
Anticancer Res; 1995; 15(2):527-9. PubMed ID: 7763034
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Ca 12-5 as a tumor marker for gastric and colo-rectal cancer in comparison to CEA and Ca 19-9.
Quentmeier A; Schlag P; Geisen HP; Schmidt-Gayk H
Eur J Surg Oncol; 1987 Jun; 13(3):197-201. PubMed ID: 3474158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
